BG60764B2 - Производно на изоксазола,метод за неговото получаване и средства,съдържащи това съединение - Google Patents
Производно на изоксазола,метод за неговото получаване и средства,съдържащи това съединение Download PDFInfo
- Publication number
- BG60764B2 BG60764B2 BG098534A BG9853494A BG60764B2 BG 60764 B2 BG60764 B2 BG 60764B2 BG 098534 A BG098534 A BG 098534A BG 9853494 A BG9853494 A BG 9853494A BG 60764 B2 BG60764 B2 BG 60764B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- formula
- compound
- carboxylic acid
- methylisoxazole
- acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000002545 isoxazoles Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title description 8
- VQBXUKGMJCPBMF-UHFFFAOYSA-N 5-methyl-1,2-oxazole-4-carboxylic acid Chemical compound CC=1ON=CC=1C(O)=O VQBXUKGMJCPBMF-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 isoxazole compound Chemical class 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 4
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000008065 acid anhydrides Chemical group 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical class CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000003931 anilides Chemical class 0.000 abstract description 7
- 239000013543 active substance Substances 0.000 abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000000202 analgesic effect Effects 0.000 abstract description 3
- 230000001754 anti-pyretic effect Effects 0.000 abstract description 3
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 230000003356 anti-rheumatic effect Effects 0.000 abstract description 2
- 239000002221 antipyretic Substances 0.000 abstract description 2
- 239000003435 antirheumatic agent Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 2
- 230000003637 steroidlike Effects 0.000 abstract description 2
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- QFQKEBLRMHMHAT-UHFFFAOYSA-N 5-methyl-3-phenylmethoxycarbonyl-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C)ON=C1C(=O)OCC1=CC=CC=C1 QFQKEBLRMHMHAT-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002134 immunopathologic effect Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001562 ulcerogenic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- SYMAGJYJMLUEQE-UHFFFAOYSA-N 3-ethoxyprop-2-enoic acid Chemical compound CCOC=CC(O)=O SYMAGJYJMLUEQE-UHFFFAOYSA-N 0.000 description 2
- ZYEWRBNSDKQNSJ-UHFFFAOYSA-N 5-methyl-n-phenyl-1,2-oxazole-4-carboxamide Chemical class O1N=CC(C(=O)NC=2C=CC=CC=2)=C1C ZYEWRBNSDKQNSJ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical compound OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- WASQWSOJHCZDFK-UHFFFAOYSA-N diketene Chemical compound C=C1CC(=O)O1 WASQWSOJHCZDFK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- SLFVYFOEHHLHDW-UHFFFAOYSA-N n-(trifluoromethyl)aniline Chemical compound FC(F)(F)NC1=CC=CC=C1 SLFVYFOEHHLHDW-UHFFFAOYSA-N 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- IAOPXZIZXDQVQM-UHFFFAOYSA-N 3,5-dioxohept-6-enoic acid Chemical compound OC(=O)CC(=O)CC(=O)C=C IAOPXZIZXDQVQM-UHFFFAOYSA-N 0.000 description 1
- KQCMLIBZCQFXJY-UHFFFAOYSA-N 3-ethoxycarbonyl-5-methyl-1,2-oxazole-4-carboxylic acid Chemical compound CCOC(=O)C1=NOC(C)=C1C(O)=O KQCMLIBZCQFXJY-UHFFFAOYSA-N 0.000 description 1
- YBLSBWHFPXDRHC-UHFFFAOYSA-N 3-methyl-1,2-oxazole-4-carboxylic acid Chemical compound CC1=NOC=C1C(O)=O YBLSBWHFPXDRHC-UHFFFAOYSA-N 0.000 description 1
- GERPXOBBNLOGFK-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-3-oxobutanoic acid Chemical compound OC(=O)CC(=O)CC1=CC=C(Cl)C=C1Cl GERPXOBBNLOGFK-UHFFFAOYSA-N 0.000 description 1
- KBFQQKBZIFSAMY-UHFFFAOYSA-N 5-methyl-n-[3-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Chemical compound O1N=CC(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1C KBFQQKBZIFSAMY-UHFFFAOYSA-N 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 241000030360 Peromyscus truei Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- DYRDKSSFIWVSNM-UHFFFAOYSA-N acetoacetanilide Chemical compound CC(=O)CC(=O)NC1=CC=CC=C1 DYRDKSSFIWVSNM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- CZGDYZDUMJDQSD-UHFFFAOYSA-N hydron;4-(trifluoromethyl)aniline;chloride Chemical compound Cl.NC1=CC=C(C(F)(F)F)C=C1 CZGDYZDUMJDQSD-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- LGVXPSMGABFXST-UHFFFAOYSA-N phenyl 5-methyl-1,2-oxazole-4-carboxylate Chemical compound C1(=CC=CC=C1)OC(=O)C=1C=NOC=1C LGVXPSMGABFXST-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950011008 tetrachloroethylene Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Lubricants (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782854439 DE2854439A1 (de) | 1978-12-16 | 1978-12-16 | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG60764B2 true BG60764B2 (bg) | 1996-02-29 |
Family
ID=6057414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG098534A BG60764B2 (bg) | 1978-12-16 | 1994-02-23 | Производно на изоксазола,метод за неговото получаване и средства,съдържащи това съединение |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US4284786A (es) |
| EP (1) | EP0013376B1 (es) |
| JP (1) | JPS5583767A (es) |
| AR (2) | AR222680A1 (es) |
| AT (1) | ATE1067T1 (es) |
| AU (1) | AU529341B2 (es) |
| BG (1) | BG60764B2 (es) |
| CA (1) | CA1129867A (es) |
| DE (2) | DE2854439A1 (es) |
| DK (1) | DK149886C (es) |
| EG (1) | EG13926A (es) |
| ES (2) | ES486758A1 (es) |
| FI (1) | FI64154C (es) |
| GR (1) | GR72731B (es) |
| HU (1) | HU178015B (es) |
| IE (1) | IE49126B1 (es) |
| IL (1) | IL58951A (es) |
| LU (1) | LU90466I2 (es) |
| MX (2) | MX6174E (es) |
| NL (1) | NL990037I1 (es) |
| NO (1) | NO148925C (es) |
| NZ (1) | NZ192400A (es) |
| PH (1) | PH16627A (es) |
| PT (1) | PT70596A (es) |
| ZA (1) | ZA796793B (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3247454A1 (de) * | 1982-12-22 | 1984-06-28 | Laboratorios Bago S.A., Buenos Aires | Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| FR2538806B1 (fr) * | 1982-12-30 | 1986-02-21 | Bago Sa Labor | Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur |
| DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US5268382A (en) * | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| US4935434A (en) * | 1988-01-26 | 1990-06-19 | Bristol-Myers Company | Antiarthritic isoxazole-4-carboxamides |
| US5258397A (en) * | 1988-11-30 | 1993-11-02 | Novapharme | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions |
| FR2662692B1 (fr) * | 1990-05-30 | 1995-04-28 | Novapharme | Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique. |
| DD297328A5 (de) * | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen |
| US5583150A (en) * | 1989-08-18 | 1996-12-10 | Alcon Laboratories, Inc. | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases |
| US5001124A (en) * | 1990-02-02 | 1991-03-19 | Syntex (U.S.A.) Inc. | 4-isoxazolecarboxamide derivatives |
| US5108999A (en) * | 1990-02-02 | 1992-04-28 | Syntex (U.S.A.) Inc. | 4-isoxazolecarboxamide derivatives |
| AU649421B2 (en) * | 1990-05-18 | 1994-05-26 | Sanofi-Aventis Deutschland Gmbh | Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs |
| DE4127737A1 (de) * | 1991-08-22 | 1993-02-25 | Hoechst Ag | Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen |
| US6133301A (en) * | 1991-08-22 | 2000-10-17 | Aventis Pharma Deutschland Gmbh | Pharmaceuticals for the treatment of rejection reactions in organ transplantations |
| EP0607777B1 (de) * | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Interleukin 8 |
| DE59407413D1 (de) * | 1993-01-08 | 1999-01-21 | Hoechst Ag | Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta |
| ATE174219T1 (de) * | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha |
| DE59407412D1 (de) * | 1993-01-08 | 1999-01-21 | Hoechst Ag | Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha |
| TW314467B (es) * | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
| DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
| LT3589B (en) | 1993-11-30 | 1995-12-27 | Hoechst Ag | Using of known combination for treatment of rejection reaction by transplantation of organs |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| US6335356B1 (en) | 1994-01-07 | 2002-01-01 | Sugen, Inc. | Method of treating a patient by parenteral administration of a lipophilic compound |
| US5519042A (en) * | 1994-01-13 | 1996-05-21 | Hoechst Aktiengesellschaft | Method of treating hyperproliferative vascular disease |
| US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
| AU695907B2 (en) * | 1994-10-17 | 1998-08-27 | Hoechst Pharmaceuticals & Chemicals K.K. | Pharmaceutical composition for prophylaxis and treatment of type I allergic diseases |
| US5721277A (en) * | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| DE19539638A1 (de) * | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| DE19702988A1 (de) * | 1997-01-28 | 1998-07-30 | Hoechst Ag | Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika |
| US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
| ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
| US7691890B2 (en) | 1998-03-11 | 2010-04-06 | James W. Williams | Anti-viral uses of leflunomide products |
| US20050255071A1 (en) * | 1998-12-10 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors |
| DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
| US6566395B1 (en) | 1999-05-25 | 2003-05-20 | Biomedicines, Inc. | Methods of treating proliferative disorders |
| DE19960443C2 (de) * | 1999-12-15 | 2002-05-08 | Aventis Pharma Gmbh | Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen |
| CZ20022000A3 (cs) * | 1999-12-16 | 2003-02-12 | Teva Pharmaceuticals Industries Ltd. | Způsoby přípravy a nová krystalická forma leflunomidu |
| EP1257270B1 (en) | 2000-02-15 | 2005-04-13 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
| EP1473035A1 (en) * | 2000-02-15 | 2004-11-03 | Teva Pharmaceutical Industries Ltd. | Leflunomide of high purity |
| US20020077485A1 (en) * | 2000-08-14 | 2002-06-20 | Ilya Avrutov | Micronized leflunomide |
| DE60226855D1 (de) | 2001-04-05 | 2008-07-10 | Aventis Pharma Inc | Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| WO2003042193A1 (en) * | 2001-11-09 | 2003-05-22 | Geneva Pharmaceuticals, Inc. | Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide |
| US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
| CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| US20060024376A1 (en) * | 2004-07-30 | 2006-02-02 | The University Of Chicago | Methods and compositions for reducing toxicity associated with leflunomide treatment |
| WO2007026737A1 (ja) * | 2005-08-31 | 2007-03-08 | Kowa Co., Ltd. | 関節リウマチの予防及び／又は治療法 |
| US9073997B2 (en) * | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
| CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
| US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
| US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ， インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
| US20230123588A1 (en) | 2020-03-06 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of slowing brain volume loss |
| WO2021189018A1 (en) | 2020-03-20 | 2021-09-23 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
| EP4415699A1 (en) | 2021-10-11 | 2024-08-21 | Laboratoires Juvise Pharmaceuticals | Methods of treating multiple sclerosis |
| US20240261268A1 (en) | 2022-02-11 | 2024-08-08 | Vanda Pharmaceuticals Inc. | Methods of slowing an increase in brain ventricular volume |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4087534A (en) * | 1974-05-22 | 1978-05-02 | David Ovadia | N-haloalkylmio urazole pesticides |
| DE2524959C2 (de) * | 1975-06-05 | 1983-02-10 | Hoechst Ag, 6000 Frankfurt | 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel |
| ES448386A1 (es) * | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
| DE2654797A1 (de) * | 1976-12-03 | 1978-06-08 | Hoechst Ag | Verfahren zur herstellung von isoxazolderivaten |
-
1978
- 1978-12-16 DE DE19782854439 patent/DE2854439A1/de not_active Withdrawn
-
1979
- 1979-12-11 ES ES486758A patent/ES486758A1/es not_active Expired
- 1979-12-11 ES ES486750A patent/ES486750A1/es not_active Expired
- 1979-12-12 EG EG748/79A patent/EG13926A/xx active
- 1979-12-13 EP EP79105142A patent/EP0013376B1/de not_active Expired
- 1979-12-13 AT AT79105142T patent/ATE1067T1/de active
- 1979-12-13 MX MX798546U patent/MX6174E/es unknown
- 1979-12-13 US US06/103,551 patent/US4284786A/en not_active Expired - Lifetime
- 1979-12-13 DE DE7979105142T patent/DE2962929D1/de not_active Expired
- 1979-12-13 FI FI793899A patent/FI64154C/fi not_active IP Right Cessation
- 1979-12-14 NZ NZ192400A patent/NZ192400A/xx unknown
- 1979-12-14 JP JP16170079A patent/JPS5583767A/ja active Granted
- 1979-12-14 AU AU53853/79A patent/AU529341B2/en not_active Expired
- 1979-12-14 DK DK534279A patent/DK149886C/da active
- 1979-12-14 HU HU79HO2201A patent/HU178015B/hu unknown
- 1979-12-14 AR AR279310A patent/AR222680A1/es active
- 1979-12-14 IE IE2426/79A patent/IE49126B1/en active Protection Beyond IP Right Term
- 1979-12-14 IL IL58951A patent/IL58951A/xx unknown
- 1979-12-14 NO NO794094A patent/NO148925C/no unknown
- 1979-12-14 CA CA342,109A patent/CA1129867A/en not_active Expired
- 1979-12-14 ZA ZA00796793A patent/ZA796793B/xx unknown
- 1979-12-14 PH PH23418A patent/PH16627A/en unknown
- 1979-12-14 GR GR60761A patent/GR72731B/el unknown
- 1979-12-14 PT PT70596A patent/PT70596A/pt active IP Right Revival
-
1981
- 1981-03-03 US US06/239,986 patent/US4351841A/en not_active Expired - Lifetime
- 1981-05-19 AR AR285378A patent/AR226894A1/es active
-
1984
- 1984-03-12 MX MX8403A patent/MX8403A/es unknown
-
1994
- 1994-02-23 BG BG098534A patent/BG60764B2/bg unknown
-
1999
- 1999-10-27 LU LU90466C patent/LU90466I2/fr unknown
- 1999-10-29 NL NL990037C patent/NL990037I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG60764B2 (bg) | Производно на изоксазола,метод за неговото получаване и средства,съдържащи това съединение | |
| SE454175B (sv) | /1-(2-bensoxazolyl, 2-benstiazolyl eller 2-indolyl)hydrazino/alkylnitrilderivat samt farmaceutiska kompositioner | |
| EP0101330B1 (en) | 2-quinolone derivatives | |
| KR860001602B1 (ko) | 피리딘 유도체의 제조방법 | |
| JPS58219161A (ja) | １，３−ジヒドロ−４−（１−ヒドロキシ−２−アミノエチル）−２ｈ−インド−ル−２−オンの新誘導体、それらの塩類、それらの製造法、薬剤としての使用及びこれらを含有する組成物 | |
| US4272507A (en) | Phenylaminothiophenacetic acids, their synthesis, compositions and use | |
| LU81565A1 (fr) | Nouvelles imidazoquinoxalines et leurs sels,leur procede de preparation,leur application a titre de medicaments et les compositions pharmaceutiques les renfermant | |
| US3812109A (en) | Substituted indenyl glucoronide esters | |
| EP0099122B1 (en) | Compositions comprising pepstatin and an histamine h2-receptor antagonist having an enhanced antiulcer activity | |
| US3773936A (en) | Method of treating inflammation with substituted anilino salicylic acids | |
| DK154136B (da) | Analogifremgangsmaade til fremstilling af 2-amino-3-benzoylphenylacetamider | |
| US4473583A (en) | Compositions containing certain derivatives of 4-phenyl-4-oxobuten-2-oic acid and methods of treatment using them | |
| JPS6310777A (ja) | ピペラジンアセトアミド誘導体 | |
| KR820002229B1 (ko) | 이속사졸 유도체의 제조방법 | |
| JPH0227325B2 (es) | ||
| EP0178121A2 (en) | Improved formulation of antiinflammatory drugs | |
| EP0440324A2 (en) | Substituted beta-diketones and their use | |
| US3985880A (en) | 2-(R'-oxymethyl)-perimidines | |
| US4333938A (en) | Imino derivatives of 5-aminobenzodioxole-1,3 which are useful as medicaments | |
| US3767811A (en) | Glyceryl n substituted phenyl anthranilates in the treatment of inflammation | |
| PT85020B (pt) | Processo para a preparacao de novos derivados do acido 4-fenil-4-oxo 2-butenoico e de composicoes farmaceuticas que os contem | |
| HU182916B (en) | Process for preparing 1,3-benzoxazine-2,4-dione derivatives | |
| US4156009A (en) | Diazepine derivatives | |
| US4565888A (en) | Substituted salicylic acid amide anthelmintics | |
| EP0068033A1 (en) | N-(4-phenyl-2-thiazolyl)carbamate derivatives, process for their preparation, and medicinal composition containing same |